Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 3,989
Out of 4,996 analysts
58
Total ratings
32.65%
Success rate
-27.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.54 | +98.56% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $18.34 | +69.03% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $0.95 | +1,900.00% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $7.39 | +184.17% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.74 | +33.69% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.66 | +863.86% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.57 | +7,543.31% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $7.09 | +252.61% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $7.75 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $6.35 | +31,396.06% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.48 | +372.97% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.41 | +314.94% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $17.50 | +242.86% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.33 | +351.13% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.95 | +153.16% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.90 | +26,620.11% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $9.38 | +1,840.30% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.21 | +37,458.69% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.51 | +343.46% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.70 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.58 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.40 | +150.00% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.08 | +245.39% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.28 | +144,101.06% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.97 | +1,778.17% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $58.50 | +412.82% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $563.90 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $82.70 | +7.62% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $142.00 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $3.81 | +393,600.79% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.48 | +13,448.39% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.52 | +298.23% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.54
Upside: +98.56%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $18.34
Upside: +69.03%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $0.95
Upside: +1,900.00%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $7.39
Upside: +184.17%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.74
Upside: +33.69%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.66
Upside: +863.86%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.57
Upside: +7,543.31%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $7.09
Upside: +252.61%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.75
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $6.35
Upside: +31,396.06%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.48
Upside: +372.97%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.41
Upside: +314.94%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $17.50
Upside: +242.86%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.33
Upside: +351.13%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.95
Upside: +153.16%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.90
Upside: +26,620.11%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $9.38
Upside: +1,840.30%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.21
Upside: +37,458.69%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.51
Upside: +343.46%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.70
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.40
Upside: +150.00%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.08
Upside: +245.39%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.28
Upside: +144,101.06%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.97
Upside: +1,778.17%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $58.50
Upside: +412.82%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $563.90
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $82.70
Upside: +7.62%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $142.00
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $3.81
Upside: +393,600.79%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.48
Upside: +13,448.39%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.52
Upside: +298.23%